Literature DB >> 10926079

Prediction of locoregional extension and metastatic disease in prostate cancer: a review.

T Reckwitz1, S R Potter, A W Partin.   

Abstract

Despite efforts to enhance the accuracy of prediction of extraprostatic disease, approximately 40% of the men undergoing radical prostatectomy are found at surgery to have non-organ-confined cancer. Predictive algorithms based on multivariate regression analysis and neural networks are widely available and are superior to our standard empirical methods of clinical staging. These algorithms have been validated in diverse and well-characterized patient groups. For enhancement of the predictive value, data input must be standardized and improved input variables must be incorporated. In addition to the three "classic" staging parameters, i.e., pretreatment prostate-specific antigen (PSA), biopsy pathology, and digital rectal examination, new variables now show promise in predicting disease extent and may be integrated in future predictive models. This review focuses on our present methods for prediction of locoregional spread and distant metastases in men with clinically localized prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10926079     DOI: 10.1007/pl00007073

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  3 in total

Review 1.  Cryotherapy.

Authors:  Katsuto Shinohara
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

Review 2.  Updated trends in imaging use in men diagnosed with prostate cancer.

Authors:  S P Porten; A Smith; A Y Odisho; M S Litwin; C S Saigal; P R Carroll; M R Cooperberg
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-05-13       Impact factor: 5.554

3.  Can we predict real T3 stage prostate cancer in patients with clinical T3 (cT3) disease before radical prostatectomy?

Authors:  Hye Won Lee; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Han Yong Choi
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.